MediWound (NASDAQ:MDWD) Earns “Buy” Rating from HC Wainwright

MediWound (NASDAQ:MDWD)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $25.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 56.15% from the company’s previous close.

MediWound Stock Performance

Shares of NASDAQ:MDWD opened at $16.01 on Friday. The business has a fifty day moving average of $17.27 and a 200-day moving average of $17.61. MediWound has a twelve month low of $11.04 and a twelve month high of $24.00. The firm has a market cap of $172.68 million, a PE ratio of -5.52 and a beta of 0.80.

MediWound (NASDAQ:MDWD) last announced its earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.50). MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same quarter in the prior year, the company earned ($0.24) earnings per share. On average, analysts anticipate that MediWound will post -2.6 EPS for the current fiscal year.

Hedge Funds Weigh In On MediWound

Several large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp bought a new stake in MediWound during the 2nd quarter worth about $342,000. Rhumbline Advisers acquired a new stake in shares of MediWound during the 2nd quarter worth approximately $131,000. Rosalind Advisors Inc. raised its stake in shares of MediWound by 22.3% during the third quarter. Rosalind Advisors Inc. now owns 628,050 shares of the biopharmaceutical company’s stock worth $11,343,000 after buying an additional 114,560 shares during the last quarter. ARK Investment Management LLC acquired a new position in MediWound in the third quarter valued at approximately $1,806,000. Finally, MetLife Investment Management LLC bought a new position in MediWound in the third quarter valued at approximately $89,000. Institutional investors and hedge funds own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.